| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:68524443:2959 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:68524443:2959?format=raw |
LEADER: 02959fam a2200433 a 4500
001 4056528
005 20221027025411.0
008 970416t19981998flua b 001 0 eng c
010 $a 97015242
020 $a0849385563 (alk. paper)
035 $a(OCoLC)36807689
035 $a(OCoLC)ocm36807689
035 $9ANC9539HS
035 $a(NNC)4056528
035 $a4056528
040 $aDNLM/DLC$cDLC$dDLC$dOrLoB-B
050 00 $aRC931.O73$bA53 1998
060 10 $aWE 250 A532 1997
082 00 $a616.7/16$221
245 00 $aAnabolic treatments for osteoporosis /$cedited by James F. Whitfield, Paul Morley.
260 $aBoca Raton :$bCRC Press,$c[1998], ©1998.
300 $a266 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aPharmacology and toxicology
504 $aIncludes bibliographical references and index.
505 00 $gCh. 1.$tOsteoporoses: Their Nature and Therapeutic Targets /$rHarold M. Frost --$gCh. 2.$tOsteoporosis - Mechanisms and Models /$rLis Mosekilde --$gCh. 3.$tPTH: Skeletal Effects in the Ovariectomized Rat Model for Postmenopausal Bone Loss /$rThomas J. Wronski and Mei Li --$gCh. 4.$tParathyroid Hormone: The Clinical Experience and Prospects /$rA. B. Hodsman, L. J. Fraher and P. H. Watson --$gCh. 5.$tAdenylyl Cyclase-Activating Anabolic Agents: Parathyroid Hormone and Prostaglandins E /$rJames F. Whitfield, Paul Morley and R. M. Langille [et al.] --$gCh. 6.$tBone Formation May Be Uncoupled from Resorption, as Demonstrated by a New Class of hPTHrP-(1-34) Analogues in Both Rapid and Slow Turnover Models of Osteopenia /$rBrain H. Vickery, Zafrina Avnur and Georgia I. McRae [et al.] --$gCh. 7.$tCommercial Exploitation of Parathyroid Hormone Therapy for the Treatment of Postmenopausal Osteoporosis /$rG. Marchand --
505 80 $gCh. 8.$tThe Insulin-Like Growth Factors: Potential Anabolic Agents for the Skeleton /$rAnna Johansson and Clifford J. Rosen --$gCh. 9.$tOsteogenic Actions of Fluoride: Its Therapeutic Use for Established Osteoporosis /$rK. H. William Lau, Kristina Akesson and Cesar R. Libanati [et al.].
650 0 $aOsteoporosis$xHormone therapy.
650 0 $aParathyroid hormone$xTherapeutic use.
650 0 $aSomatomedin$xTherapeutic use.
650 12 $aOsteoporosis$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D010024Q000188
650 22 $aParathyroid Hormone$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D010281Q000627
650 22 $aProstaglandins E$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D011458Q000627
650 22 $aFluorides$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D005459Q000627
700 1 $aWhitfield, James F.$0http://id.loc.gov/authorities/names/n82148506
700 1 $aMorley, Paul,$cPh. D.$0http://id.loc.gov/authorities/names/n97801476
830 0 $aPharmacology & toxicology (Boca Raton, Fla.)$0http://id.loc.gov/authorities/names/n88525784
852 00 $boff,hsl$hRC931.O73$iA53 1998